• Product NameCrizotinib (PF-02341066)
• Brief DescriptionInhibitors
• Purification98.97%
• Biological ActivityCrizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung Y (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
• Target NameALK inhibitor; c-Met/HGFR inhibitor
• CAS No. 877399-52-5
• Calculated MW 450.34
• Formulation C21H22Cl2FN5O
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
  Pathways:Angiogenesis; Tyrosine Kinase/Adaptors
  Receptor:ALK; c-Met
  Boling pt:599.18C
  Melting pt:
  Solubility:DMSO: 9 mg/mL (19.98 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Zou HY, et al. Y Res. 2007, 67(9), 4408-4417.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting